Indeed, clinical trials to investigate treatment with IL-18BP for adult-onset Still’s Disease and NLRC4-associated macrophage activation syndrome, inflammatory diseases associated with high plasma IL-18 levels, are ongoing [120,121,122] (ClinicalTrials.gov Identifier: NCT 02398435, NCT 03113760). This evidence concerns the gene NLRC4 and macrophage activation syndrome.